Pharmaceuticals Expert Witnesses

Pharmaceuticals expert witnesses and consultants listed here may be able to form expert opinions, draft expert witness reports, provide expert witness testimony at deposition and/or trial as or serve as consulting (non-testifying) experts on pharmaceuticals. The pharmaceuticals expert witness listings on this page are typically from fields/areas of expertise such as: Financial, Pediatric Hematology Oncology, Pharmacology, and Toxicology.

James C. Norris, PhD, DABT, ERT Norris Consulting Services

Benton, Arkansas
Toxicology, Pharmacology - Inhalation, pharmaceuticals, chemicals, combustion/fire, pesticides, carcinogenicity
Dr. Norris has training in pharmacology and toxicology and has been practicing for over 30 years. He has testified to governmental agencies, served on an industrial site crisis team, and acted as a media consultant. He served as an expert witness in the US, UK and Hong Kong. He also is a testifying expert witness in US Air Force and US Navy court martials.

Ilonna J. Rimm, MD PhD CFA Rimm Healthcare Capital Advisory LLC

Newton Center, Massachusetts
Financial, Pediatric Hematology Oncology - Appraisal and Valuation, Banking, Business Valuation, DNA, Financial, Securities and Investments, Biotechnology, Medical Devices, Healthcare Services, Life Science Tools , Pharmaceuticals , Entrepreneurial Companies, Start-up companies
Ilonna Rimm can provide expert witness services related to valuation and financial analysis of Healthcare Companies, including Biotech, Medical Device, Healthcare Services and Life Science Tools companies. Ilonna Rimm, MD PhD CFA, is a healthcare investor who provides strategic advice on raising early-stage capital. As the CEO and Founder of Morninglight Healthcare Capital, LLC, a family office, she invests in small cap public companies (0 to $4B market cap). She also serves as an Advisor to Life Sciences CEO’s who are raising a Seed or Series A Round of capital, as Rimm Healthcare Capital Advisory, LLC. She can fully understand the biological science of an emerging company. Then she can organize and polish the science to present it in a way that is attractive to life science investors. She recently provided services to Immuneering Corp., who raised a Series A round of $20M in January, 2020, and a Series B round of $62M in January, 2021. Immuneering is now a public company (IM...